What’s Next for Oncology Care Management and Payment?

Summary

Avalere experts took a closer look at emerging oncology trends, innovative approaches to payment and delivery, and what these changes will mean for patient access.

Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Access Recording

Access Webinar Slides

Sophisticated treatment advancements will continue to evolve how oncology stakeholders define value and manage cancer care during and after COVID-19. Join Avalere experts as they take a closer look at emerging trends, innovative approaches to payment and delivery, and what these changes will mean for patient access.

Key Topics

COVID-19 impacts on oncology care delivery, cost, and outcomes
Oncology payment and delivery reform amid a public health emergency
Managing and paying for emerging therapies and cancer combo regimens
2020 election implications for the future of oncology care

Panelists

Moderator

Sarah Butler , Head, Client Solutions, Marketing & Operations

Sarah Butler specializes in evidence-based medicine, value-based contracting, and strategy development.

Speaker

Lance Grady , Executive Vice President, Life Sciences Strategy & Growth

Lance Grady is the head of Avalere’s Life Sciences Strategy & Growth.

Speaker

Milena Sullivan , Managing Director, Policy

Milena Sullivan advises life sciences clients on the impact of the evolving healthcare policy landscape on their commercial, access, and advocacy priorities.

Guest Speaker

Roy Beveridge, MD , Senior Advisor, Avalere Health

Dr Beveridge is part of Avalere’s Commercialization and Regulatory Strategies team and helps as a senior advisor; He is a medical oncologist who has been in practice for more than 20 years.